Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976275 | 0.75 | CARM1 (0.49) | CYP2D6CYP2C9CYP2C19MAOBCYP3A4 | |
| SCHEMBL16033388 | 0.74 | KDM5A (0.73) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL13681921 | 0.74 | MAOB (0.50) | MAOBCARM1PRMT6PRMT8MAPK13 | |
| SCHEMBL17710641 | 0.72 | KDM5B (0.43) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL16034354 | 0.71 | KDM4C (0.59) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL17503790 | 0.70 | KDM5B (0.36) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL6840156 | 0.69 | CYP1A2 (0.73) | CYP2D6CYP2C9CYP2C19MAOBCYP3A4 | |
| SCHEMBL16033474 | 0.68 | KDM5A (0.67) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL16034190 | 0.68 | KDM5A (0.71) | KDM4AKDM4CKDM5AKDM5BKDM2B | |
| SCHEMBL20550782 | 0.67 | KDM4C (0.39) | KDM4AKDM4CKDM5AKDM5BKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9701657-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PDK1 406/4885KDM4A 12/4885KDM4C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.